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http://dx.doi.org/10.1016/j.ccr.2014.01.030SUMMARYThe mutagenic effect of hepatitis B (HBV) integration in predisposing risk to hepatocellular carcinoma (HCC)
remains elusive. In this study, we performed transcriptome sequencing of HBV-positive HCC cell lines and
showed transcription of viral-human gene fusions from the site of genome integrations. We discovered
tumor-promoting properties of a chimeric HBx-LINE1 that, intriguingly, functions as a hybrid RNA. HBx-
LINE1 can be detected in 23.3% of HBV-associated HCC tumors and correlates with poorer patient survival.
HBx-LINE1 transgenic mice showed heightened susceptibility to diethylnitrosamine-induced tumor forma-
tion. We further show that HBx-LINE1 expression affects b-catenin transactivity, which underlines a role in
activating Wnt signaling. Thus, this study identifies a viral-human chimeric fusion transcript that functions
like a long noncoding RNA to promote HCC.INTRODUCTION
Chronic hepatitis B (HBV) infection is a major risk factor for the
development of hepatocellular carcinoma (HCC). Chronic HBV
carriers are believed to be at 100–200 times increased risk of
developing HCC compared to noncarriers (El-Serag and Ru-
dolph, 2007). Several direct and indirect mechanisms of the viral
induction toward HCC formation have hence been proposed.
Long-lasting viral multiplications and expression of HBV proteins
are known to stimulate host immune response, leading to liver
inflammation, cirrhosis, and ultimately cancer (Chisari and Fer-
rari, 1995). On the other hand, a more direct effect of HBV inte-
grations on hepatic carcinogenesis has been postulated based
on the fact that 85%–90% of HBV-associated HCC tumors har-Significance
The biological consequences of HBV integration in cis activatio
moting HCC development are still largely unclear. Our whole-
transcription of chimera viral-human sequences as a conseque
of functionality of a long noncoding RNA-like transcript, HBx-
Wnt/b-catenin signaling pathway activation. Reports on HB
impacts; our findings establish a clear functional role by whic
our data provide pathogenic insights into a hybrid RNA in HCC
complexity in viral oncogenesis.bor one or more sites of HBV insertion (Bre´chot et al., 2000). The
majority of HCC tissue also exhibits clonal expansion of tumor
cells carrying the same integration sites (Gozuacik et al., 2001).
Implication of viral integrants in promoting HCC development
has thus long been suggested, although details of the induced
carcinogenetic changes remain elusive.
Earlier reports of isolating HBV integrants using PCR-based
methods suggested that the insertional sites occurred randomly
throughout the whole genome, leading to the presumption that
there were no preferential sites of integration (Matsubara and
Tokino, 1990). More recent high-throughput next-generation
sequencing studies have begun to reveal a few recurrent sites
of insertion and showed that many HBV integrants actually occur
within or near repetitive sequences, such as long interspersedn of gene expression and the functional implications of pro-
transcriptome study describes key features of readthrough
nce of genome integration. Specifically, we provide evidence
LINE1, which confers cancer-promoting properties through
V integrants have often failed to address their biological
h viral insertion can support cancer development. In sum,
development and highlight an additional layer of molecular
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Table 1. Detection of HBV-Human Chimeric Transcripts from Transcriptome Analysis
Cell Lines
Interrupted
HBV ORF
Integrated Human Gene or
Sequence Location Description
HKCI-4 surface CHIC2 intron 3 cysteine-rich hydrophobic domain 2 protein
surface TERT upstream telomerase reverse transcriptase
X LINE1 on chr8p11 long-interspersed nuclear element 1 sequence
core chr.5q14a-RALGPS1 intron 3
(complex fusion)
Ral guanine nucleotide exchange factor with pleckstrin homology domain
and avian sarcoma viral oncogene homology 3-binding motif 1
surface UPF3A exon 10 UPF3 regulator of nonsense transcripts homolog A
HKCI-5B core ZNF48 intron 2 zinc finger protein 48
core CDHR3 exon 19-TRRAP intron 27
(complex fusion)
Cadherin-related family member 3; transformation/transcription domain-
associated protein
X METAP1 intron 1 methionyl aminopeptidase 1
HKCI-7 core LINE2 on chr11q13 long interspersed nuclear element 2 sequence
polymerase TPCN2 intron 21 two-pore segment channel 2
HKCI-11 X SINE on chr4q12 short interspersed nuclear element sequence
aHuman sequence showed partial homology to regional chr.5q14.
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Chimeric Transcription at Viral Integration Sitenuclear elements (LINEs), short interspersed nuclear elements
(SINEs), and Alu (Ding et al., 2012; Fujimoto et al., 2012; Sung
et al., 2012). The most common cellular gene associated with
viral integration to date is the telomerase reverse transcriptase
gene (TERT), where insertions within the gene or upstream of
the promoter have been described. The human TERT encodes
the telomerase catalytic subunit, which is an essential compo-
nent for maintenance of telomere length. Because aberrant
overexpression of TERT is associated with tumor development
(Cohen et al., 2007), it is hypothesized that viral integration in
the TERT locusmay confer early clonal advantage during chronic
HBV infection.
Notably, recent deep-sequencing studies of HBV integrations
in HCC have illustrated findings mostly from whole-genome
sequencing (Fujimoto et al., 2012; Jiang et al., 2012) or targeted
sequencing of enriched HBV integrants (Ding et al., 2012). These
studies all focused on viral genomic integration sites and occa-
sionally the effect of such integration on host cellular gene
expression. The functional consequences of genome disruption
by viral insertions, particularly those associated with repetitive
sequences, however, have been minimally addressed and
remain to be determined. In this study, we attempted to decon-
volute HBV junctures at the whole-transcriptome level with an
aim toward characterizing the transcribed viral-human fusions
and the cis effect on cellular gene expression from the juxtapo-
sition of HBV. To aid our analysis, we developed an algorithm,
ViralFusionSeq (VFS) (Li et al., 2013), that allows accurate and
unbiased detection of fusions between viral and human se-
quences as well as complex fusion events. We examined
whether direct transcription of HBV-human sequences could
result from the site of genome insertions, and whether viral inte-
gration could activate transcription of normally silent sequences
such as LINEs and SINEs. Here we also provide detailed charac-
terization of the biological functions of a specific chimeric tran-
script, HBx-LINE1, that we discovered through the VFS screen.
A major goal of this study was to provide evidence for tumori-
genic activity of HBx-LINE1 and to identify the mode of action
responsible for its oncogenicity.336 Cancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc.RESULTS
HBV-Human Chimeric Transcripts
We performed transcriptome sequencing to survey six HBV-
positive HCC cell lines for viral integrants. Chimeric viral-human
transcripts were identified in four cell lines: HKCI-4, -5B, -7,
and -11. A total of 11 flanking cellular sequences was isolated,
where more than one chimeric transcript could be detected in
each specimen, except HKCI-11 (Table 1). Many of the flanking
sequences were from the human intergenic regions that con-
tained a portion of a repetitive element such as a LINE or SINE
(Table S1 available online). Other fusion sequences containing
part of cellular genes, including CHIC2, UPF3A, ZNF48,
METAP1, and TPCN2, were detected. Transcript fusion from
the proximal insertion upstream of TERT could also be found.
Interrupted HBV open reading frames (ORFs) were common in
the surface gene (HBs), X gene (HBx), and between X and core
(HBc) regions (Table 1).
We attempted validation of chimeric sequences and also
investigated for their corresponding genomic sites that might
underlie the chimeric transcriptions. By Sanger sequencing, we
confirmed all VFS-identified viral-human transcripts. Moreover,
RNA sequences obtained in the chimeras matched the flanking
virus-host juncture of genomic sites with identical overlapping
microhomologies (Figure S1A). In addition to directing viral
integrations in cellular genes, an integration event in genomic re-
gions that have undergone possible complex genomic rear-
rangement was found in two cases: a CDHR3-TRRAP fusion
and a chr.5q14-RALGPS1 fusion (Figure 1A; Figure S1A).
Of particular interest was the finding of a cryptic splicing event
resulting from a viral insertion into UPF3A. In HKCI-4, truncated
HBs were transcribed together with UPF3A exon 10. However,
the genomic breakpoints of viral and human sequences that
flanked the junctures were dissimilar to the chimeric transcript;
instead, HBs DNA (nt 318–2232) was shown to be inserted into
intron 9 of UPF3A. The HBs gene contains a CAAGG sequence
(nt 455–459), which is identical to the last 5 nt of UPF3A
exon 9. It is plausible that during RNA splicing a cryptic splice
AB
C
Figure 1. Illustration of Viral-Human Chimeric Transcripts and Sanger Sequencing Validation
(A) Viral insertion into genomic rearrangement of CDHR3-TRRAP in HKCI-5B resulted in complex fusion transcription of HBc-CDHR3-TRRAP.
(B) Cryptic splice site from viral integration. VFS identified an in-frame fusion transcript of HBs-UPF3A exon 10, whereas Sanger sequencing showed genomic
insertion of HBs into UPF3A intron 9. An identical sequence motif, CAAGG (nt 455–459), could be found in the HBs gene and the splice junction ofUPF3A exon 9.
(C) Chimeric fusion of interrupted HBs ORFs and the human sequence upstream of TERT was detected by VFS in HKCI-4 and validated by Sanger sequencing.
The figure highlights unique clipped-seq fragments of flanking viral and human regions with themicrohomology sequence underlined. The cis effect on TERT gene
expression from proximal viral insertion was examined in HKCI-4 and other cell lines without nearby insertion. The arrow denotes the site of integration.
See also Figure S1 and Tables S1 and S2.
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(nt 459–2232) and the formation of an in-frame chimeric fusion
of HBs-UPF3A exon 10 (Figure 1B).
Expression of Silent Genomic Regions from Viral
Integration
A possible oncogenic contribution of HBV DNA integration to
cellular genes is the activation of transcriptional activities. To
study this cis-acting effect, we examined the expression levels
based on FPKM values (fragments per kb of exon per million
fragments mapped) of nearby protein-coding genes with viralinsertion. Although direct disruption of gene structure from viral
DNA integration was found, an effect on cellular gene expression
was not apparent. Cellular genes with or without viral insertion
showed similar expression levels, suggesting that an effect on
gene expression may not be evident (Figure S1B). We also sur-
veyed the expression levels (in terms of FPKM) of genes located
within 100 kbp upstream or downstream of all VFS-identified
viral insertion sites. A direct correlation between expression level
of a gene and its physical distance from the viral integration site
was not observed (Figure S1C). The possible cis-regulatory
effect of a viral insertion event on nearby genes would seemCancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc. 337
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Figure 2. HBV Integration Can Activate Transcription of the Silent LINE1 Region
(A) Readthrough transcription of HBx-LINE1 from juxtaposed viral insertion into the chr.8p11.21 LINE1 region. RNA-seq data on liver tissue (Cabili et al., 2011),
BodyMap 2.0 project on healthy liver samples (Sequence Read Archive accession number GSE30611), and transcriptome array on normal livers (Xu et al., 2011)
signify the chr.8p11.21 LINE1 region as a transcriptionally silent heterochromatin. Cell lines without viral insertion in the region do not display any LINE1
expression. The partial HBx-LINE1 transcript sequence reconstructed using only the RNA-seq data is shown.
(B) Cell line HKCI-4 was established by our laboratory (Pang et al., 2002), and the corresponding patient’s HCC tumor (PHCC-4) was examined for the presence of
the chimeric HBx-LINE1 transcript. RT-PCR analysis for HBx-LINE1 expression in HKCI-4 and the parental tumor PHCC-4 is shown. The cell line HKCI-9 and
(legend continued on next page)
Cancer Cell
Chimeric Transcription at Viral Integration Site
338 Cancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc.
Cancer Cell
Chimeric Transcription at Viral Integration Sitenot to be apparent, although the involvement of trans-acting
mechanisms cannot be ruled out.
Interestingly, we found active transcription of readthrough hu-
man sequences from regions that are normally silent in the
genome. For instance, an HBV insertion upstream of TERT did
not elevate TERT expression compared to other samples, but
the transcribed sequence was derived from a region of nontran-
scribing DNA (Figure 1C). Remarkably, a LINE1 sequence was
cotranscribed from the HBV insertion into chr.8p11 in HKCI-4
(Figure 2A). This LINE1-rich region lies within the transcriptionally
silent heterochromatin of chr.8p11.21 with no transcription
factor binding sites as indicated by the ENCODE data set
(https://genome.ucsc.edu/ENCODE). Both RNA sequencing
(RNA-seq) data of multiple tissue types in the BodyMap
2.0 project (http://www.ebi.ac.uk/arrayexpress/experiments/
E-MTAB-513) (Sequence Read Archive accession number
GSE30611) and healthy liver samples (Cabili et al., 2011; Xu
et al., 2011) also denote chr8, 41485000–41500000 nt, as a non-
transcribing region in the human genome (Figure 2A). The dis-
covery of a profound virus-driven LINE1 expression prompted
our further investigations of the chimeric transcript HBx-LINE1.
Expression of other silenced genomic regions from juxtaposition
of viral insertion could also be found for HBc-LINE2 (average
read depth 10.69 FPKM) and HBx-SINE (average read depth
11.11 FPKM) in HKCI-7 and HKCI-11, respectively, but their
expression levels are lower than HBx-LINE1 (average read depth
60.35 FPKM).
Expression of HBx-LINE1 in HCC Tumors and Cloning of
Full-Length Transcripts
We first confirmed HBx-LINE1 expression in HKCI-4 by RT-PCR
and Sanger sequencing (Figure 2B). To rule out the possibility
that HBV insertion was introduced as a result of prolonged
in vitro culture, we examined the parental HCC tumor of
HKCI-4 for the hybrid transcription. The primary tumors were
accessible because the HKCI series of cell lines was established
by our laboratory (Pang et al., 2002; Chan et al., 2006). Cell line
HKCI-4 and its parental HCC tumor (PHCC-4) showed the
consistent presence of the HBx-LINE1 hybrid transcript. In
conjunction, we also examined HKCI-9, which served as a
negative control. The expression of HBx-LINE1 was further
demonstrated by in situ hybridization. Using a probe comple-
mentary to the viral-human juncture, intense cytoplasmic signal
of the HBx-LINE1 transcript was detected in HKCI-4 but not
HKCI-9 (Figure 2B).
We proceeded to clone the full-length HBx-LINE1 transcript in
HKCI-4. By 50 and 30 rapid amplification of cDNA ends (RACE)
clonings, we isolated a 30 transcript of LINE1 that contained
the polyadenylation signal AATAAA and a poly(A) tail and a 50
transcript entailing a C-terminal truncated HBx (Figure S2). The
combined 30 and 50 end RACE enabled a full-length HBx-LINE1parental tumor PHCC-9 pair served as negative control. In situ hybridization for
represent 50 mm.
(C) Schematic diagram of the HBx-LINE1 flanking sequence. RACE cloned a full-l
stop codon on chr.8p11. The viral DNA sequence upstream of the HBx ORF was e
transcript is shown with numbers denoting nucleotide position. Blue highlights t
microhomology at both breakpoint junctions is underlined.
See also Figure S2.transcript of 674 bp to be achieved (Figure 2C). The fusion tran-
script entailed 297 bp from HBx that ranged from 1,326 to
1,622 nt of the HBV genome and 380 bp of LINE1 from
chr.8p11 that spanned position 41493923–41494302 nt. There
was a 3 bp microhomology at both breakpoint junctions, where
the 50 end of the HBx sequence shared a GTG sequence with the
30 end of the LINE1 sequence. We further examined the up-
stream viral sequence of the genomic integration site. By primer
walking, we determined the promoter of HBx 50 upstream of the
truncated HBx (Figure 2C), suggesting a possible viral promoter-
driven transcription of the HBx-LINE1 fusion.
The incidence of the HBx-LINE1 chimeric transcript was
examined in a cohort of 90 HBV-associated HCC tumors.
Hemi-nested RT-PCR analysis indicated expression of HBx-
LINE1 in 21 of 90 cases (23.3%) (Figure 3A). To corroborate
the presence of this HBx-LINE1 fusion transcript, all PCR prod-
ucts from primary tumors were sequence verified (Figure 3A; Fig-
ures S3A and S3B). In all cases, the exact viral-human flanking
sequence was found. We extended our study to investigate the
association of HBx-LINE1 expression with prognosis of HCC
patients. Kaplan-Meier analysis indicated that the presence of
the HBx-LINE1 transcript could predict a shorter overall survival
of patients (p = 0.0154; Figure 3B). Further univariate and multi-
variate Cox regression analyses suggested that HBx-LINE1
expression remained a significant independent predictor of
patient survival (p = 0.0165; Figure 3C) in addition to microvas-
cular invasion. We also asserted the presence of HBx-LINE1
by an independent assay of real-time PCR using a custom probe
that flanked the viral-human junction. In 20 HBV-associated
tumors examined, HBx-LINE1 expression could be detected in
6 cases (30%) with estimated transcript levels ranging from
13,875 to 79,525 copies/mg RNA (Figures S3C–S3E).
We also examined the recurrence incidence of ten remaining
viral-human chimeras discovered from the transcriptome
(Table 1). Recurrence was not suggested for eight chimeric tran-
scripts in 66 HBV-associated HCC tumors examined; only HBs-
UPE3Awas found in two cases (2/66; 3.03%) and HBx-METAP1
in one case (1/66; 1.52%) (Figure S3F).
HBx-LINE1 Promotes Cell Motility through Epithelial-to-
Mesenchymal Transition
We postulated that the high prevalence of HBx-LINE1 expres-
sion in HCC may hold biological significance. To elucidate the
potential functional contributions from this chimeric transcript,
knockdown experiments with two small interfering RNAs
(siRNAs), siHBx-LINE1a and siHBx-LINE1b, were performed in
HKCI-4. The knockdown efficiencies were confirmed by quanti-
tative (q)RT-PCR (Figure 4A). Whereas siRNA-mediated target-
ing of HBx-LINE1 did not seem to affect cell viability, more
apparent effects were indicated from Transwell migration and
Matrigel invasion (Figures 4B and 4C). Both siHBx-LINE1a andHBx-LINE1 transcript in HKCI-4 and HKCI-9 is also presented. The scale bars
ength transcript of 674 bp with an ATG start codon indicated in HBx and a TGA
xamined by primer walking. The sequence of the 674 bp full-length HBx-LINE1
he viral sequence and black highlights the human sequence, and a 3 bp GTG
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Figure 3. Expression of HBx-LINE1 in Primary HCC
(A) Representative images of RT-PCR analysis of the HBx-LINE1 transcript in primary HCC tumors. NTC, no template control. All PCR bands were also subjected
to sequence verification by Sanger sequencing.
(B) Kaplan-Meier curves depicting HCC patients with positive (dotted line) and negative (solid line) expression for HBx-LINE1.
(C) Univariate and multivariate Cox regression analysis for poor prognostic factors affecting overall survival of HCC patients. +Age: age %40 versus
age >40. *Clinical stage: T1 versus T2 versus T3. Tumor stage is classified according to American Joint Committee on Cancer tumor-node-metastasis
staging criteria (Greene et al., 2002). #Tumor grade: poorly differentiated versus moderately differentiated versus well-differentiated. ^Macrovascular
invasion, ^microvascular invasion, and ^cirrhosis: presence versus absence. ITumoral lesions: solitary versus multiple.
See also Figure S3 and Table S3.
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properties of HKCI-4 cells compared to siMock control. Because
the phenomenon of epithelial-to-mesenchymal transition (EMT)
is a major molecular mechanism by which cancer cells acquire
motile ability to invade the tumor microenvironment, we further
investigated the effect of HBx-LINE1 on the modulation of
EMT. Western analysis of siHBx-LINE1-treated HKCI-4 revealed
increased expression of epithelial markers E-cadherin and
g-catenin and diminution of themesenchymal protein fibronectin
(Figures 4D and 4E). These findings were further substantiated in
immunofluorescence analysis, which corroborated the augmen-
tation of E-cadherin and g-catenin expression and their promi-
nent accumulation at the cell membrane in siHBx-LINE1-treated
cells. In comparison, a more diffuse cytoplasmic localization of
these markers was suggested in both siMock and Lipofect-
amine-treated control cells. A decrease in the level of cyto-
plasmic fibronectin was also observed in siHBx-LINE1-treated
cells relative to control treatments (Figure 4F).340 Cancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc.HBx-LINE1 Activates Wnt/b-Catenin Signaling
It is known that b-catenin forms amembranous complex with the
cell-adhesion protein E-cadherin and other catenin proteins.
During the process of EMT, b-catenin is dissociated from the
membrane-associated E-cadherin complex and then translo-
cates to the nucleus, where it activates the Wnt signaling
pathway (Polette et al., 2007). To examine whether HBx-LINE1
has an effect on Wnt/b-catenin signaling, we next examined
the nuclear localization and transactivity of b-catenin under the
influence of HBx-LINE1. In HKCI-4 cells treated with siHBx-
LINE1a and siHBx-LINE1a, an effect on the total cellular b-cate-
nin protein was not suggested but both siRNAs concurred to
suggest a reduced level of active b-catenin by western blot
(Figure 4G). By TOP/FOPflash assay, we found a reduced
transactivation activity of b-catenin following HBx-LINE1 knock-
down, which is in line with the lowered active b-catenin protein
found (Figure 4H). Cellular distribution of b-catenin as revealed
from immunofluorescence staining also indicated diminution of
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Figure 4. Knockdown of HBx-LINE1 Inhibits Cell Motility through Regression of EMT
(A) Efficacy of siHBx-LINE1a and siHBx-LINE1b confirmed by qPCR.
(B) Relative cell migration and invasion in cells treated with siHBx-LINE1a and siHBx-LINE1b compared to Lipo and siMock controls.
(C) Effect on cell viability by MTT assay.
(D) Western blot analysis of E-cadherin and g-catenin (epithelial markers) and fibronectin (mesenchymal marker) in siHBx-LINE1a and siHBx-LINE1b knockdown
cells compared to siMock and Lipo controls.
(E) Densitometry measurements of western blots from three independent experiments.
(F) Immunofluorescence staining for the EMT process. Expression of adhesion proteins E-cadherin and g-catenin and cytoplasmic fibronectin in siHBx-LINE1a-
and siHBx-LINE1b-treated cells is illustrated. Nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI).
(G) Western blot for active and total b-catenin levels.
(H) TOP/FOPflash reporter assay for b-catenin transactivity.
(I) Immunofluorescence staining for b-catenin in HBx-LINE1 knockdown cells compared to siMock and Lipo controls.
The scale bars represent 10 mm. All data shown are mean ± SEM from three independent experiments (**p < 0.01, *p < 0.05).
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and siHBx-LINE1b, whereas Lipofectamine-treated and siMock
control cells showed more intense accumulation of b-catenin
within the nucleus (Figure 4I).
HBx-LINE1 Exerts Functional Effects as a Long
Noncoding RNA-like Transcript
To determine whether the viral component, human sequence,
or full-length HBx-LINE1 underlies the functional effects ob-
served, we next cloned and expressed the full-length HBx-
LINE11–674 and variants including HBx-LINE11–312*, HBx1–297,
and LINE1295–674 for translated proteins (Figure 5A). GFP-fused
protein expressed from these clones showed protein sizes in
accordance with prediction, where minimal differences could
be detected between proteins translated from HBx-LINE11–674
and HBx-LINE11–312* (Figure 5B). Translated proteins from full-
length HBx-LINE11–674 showed a 48.4 kDa protein that is analo-
gous to the HBx-LINE11–312* variant. Both constructs translated
82 amino acids from the truncated HBx region and an extra
5 amino acids from the LINE1 human region, which harbored
a stop codon at position 310–312 nt (Figure 5A). Immunofluores-
cence analysis showed a diffuse cytoplasmic distribution in
cells transfected with HBx-LINE11–674 that was similar to the
other three constructs and GFP-vector alone (Figure S4A).
Transcribed RNA of the cloned inserts HBx-LINE11–674, HBx-
LINE11–312*, HBx1–297, and LINE1295–674 from GFP-deleted
C2R(-) constructs was also assessed in transfected L02, and
the molecular weights determined were in concordance with
predicted size (Figure 5B).
In vitro functional investigations in immortalized human hepa-
tocyte cell line L02 showing only cells expressing full-length
HBx-LINE11–674 displayed noticeable colony growth, whereas
expression of HBx-LINE11–312*, HBx1–297, and LINE1295–674
showed similar effects as the vector control (Figure 5C). The pos-
sibility of functional augmentation being attributed to a viral-
human fusion protein was eliminated by the fact that protein
translated from HBx-LINE11–674 was analogous to HBx-
LINE11–312*, and no growth advantage was conferred by
HBx-LINE11–312*. In addition, transfection of full-length HBx-
LINE11–674 and truncated mutants in L02 suggested only HBx-
LINE11–674 could promote cellmigration and invasion (Figure 5C).
We further explored the changes in EMT markers, but it was
noted that L02 failed to show detectable E-cadherin expression
in repeated experiments. We hence replaced E-cadherin withFigure 5. Full-Length HBx-LINE1-Mediated b-Catenin Activation Prom
(A) Schematic diagram of constructs of full-length HBx-LINE11–674, HBx1–297, LIN
vector, respectively. Each plasmid was cloned into two expression vectors, pEGFP
coding sequence, were examined for tag-fused protein translation and localizatio
GFP sequence, was used in all functional assays described. CMV, cytomegalov
(B) GFP-conjugated protein translation and RT-PCR analysis in L02.
(C) Effect of full-length and truncated variants on cell growth, migration, and inva
(D and E) Effect of HBx-LINE11–674 and truncated variants on the EMT process in
(F) Effect of full-length and truncated variants on cell growth, migration, and inva
(G) TOP/FOPflash assay for b-catenin transactivity in L02, HKCI-9, and HKCI-1.
(H) Immunofluorescence analysis for b-catenin localization in transfected L02 ce
(I and J) Western analysis and densitometry measurements for changes in EMT
(K) Immunofluorescence results in HKCI-9.
The scale bars represent 10 mm. All data represent mean ± SEM values from th
nificance). See also Figure S4.another epithelial marker, CK18, and included a hallmarkmarker,
N-cadherin, for the mesenchymal change. Remarkably, marked
expression and typical localization of N-cadherin to the cell
membrane was evident in HBx-LINE11–674-transfected L02,
signifying a mesenchymal change (Figures 5D and 5E). A corre-
sponding increase in the expression of fibronectin was also
found in HBx-LINE11–674-transfected cells. Expression of CK18
and g-catenin, on the other hand, was reduced following HBx-
LINE11–674 transfection, but not with other variant constructs
and the vector control (Figures 5D and 5E). We also examined
the functional effects of these expressing vectors in HKCI-9
and HKCI-1 and found a similar enhancement in cell growth
and motility from the ectopic expression of HBx-LINE11–674 (Fig-
ure 5F; Figures S4B and S4C). This stimulation corresponded to
an increased TOP/FOP transactivity, which was persistently
higher in all three cell lines transfected with HBx-LINE11–674
but not HBx-LINE11–312* (Figure 5G). Image analysis showed
nuclear localization of b-catenin with HBx-LINE11–674 but not
other variants (Figure 5H).
To affirm involvement of the EMT process in HKCI-9 and
HKCI-1 as well from the transfection of HBx-LINE11–674, western
analysis showed an increased expression of fibronectin and
downregulation of E-cadherin and g-catenin (Figures 5I and
5J). The change in level of these protein markers also corre-
sponded to immunofluorescence imaging, where marked
reduction in the membranous localization of epithelial adhesion
molecules was found and prominent fibronectin cytoplasmic
localization was shown (Figure 5K; Figure S4D). More notably,
western analysis also revealed the level of activated b-catenin
to be consistently elevated in all three cell lines when subjected
to full-length HBx-LINE11–674 induction, but this phenomenon
was not found with other truncated variants (Figure 6A). Our
data would imply that protein translated from HBx-LINE11–674
cannot account for the distinct functional phenotypes observed
from ectopic expression. It is hence conceivable that HBx-
LINE11–674 exerts its functional effects as a long noncoding
RNA (lncRNA)-like transcript.
To assert that HBx-LINE11–674 functions as a hybrid RNA, we
further constructed amutant with a stop codon introduced at the
beginning of HBx, so that the protein translation was inhibited
but RNA production was maintained (Figures 6B and 6C). Both
HBx-LINE1mutant and HBx-LINE11–674 were examined for func-
tionality in colony-forming growth and migratory ability. We
found that the HBx-LINE1 stop mutant expressed in L02 andotes Cell Growth and Motility through EMT Progression
E1295–674, and HBx-LINE11–312*.: and D denote stop codons on LINE1 and
-C2 and pEGFP-C2R(-). Plasmids cloned into a pEGFP-C2 vector, with aGFP-
n. The series of plasmids cloned into the pEGFP-C2R(-) vector, with a deleted
irus.
sion analysis in L02.
L02. Results from western blot and immunofluorescence imaging are shown.
sion analysis in HKCl-9.
lls.
markers in HKCI-9 and HKCI-1.
ree independent experiments (***p < 0.001, **p < 0.01, *p < 0.05; n.s., no sig-
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Figure 6. HBx-LINE1 Exerts Functional Effects as a Long Noncoding RNA-like Transcript
(A) Western analysis of active b-catenin in the presence of HBx-LINE11–674, HBx-LINE1mutant, and truncated variants in L02, HKCI-9, and HKCI-1.
(B) Schematic diagram of HBx-LINE11–674 and HBx-LINE1mutant; the latter harbors a stop codon (red arrowhead) on HBx.
(C) Northern blot shows HBx-LINE11–674 and HBx-LINE1mutant transcripts at the expected length of900 bp (674 bp from HBx-LINE1 to the vector frame poly[A]
tail of 220 bp). In vitro translation showed a protein band from HBx-LINE11–674 (red arrowhead) at the predicted size of 11.4 kDa. No evident band could be
detected from HBx-LINE1mutant.
(legend continued on next page)
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Cancer Cell
Chimeric Transcription at Viral Integration SiteHKCI-9 showed similar colony-formation ability as HBx-
LINE11–674, which emphasized the activity being derived from
the RNA transcript independent of its coding capacity (Fig-
ure 6D). To affirm the function of HBx-LINE1mutant in cancer
cell motility, we further conducted rescue experiments in
HKCI-4 by reintroducing HBx-LINE1mutant or HBx-LINE11–674 in
the presence of si knockdown of HBx-LINE1. We found that
ectopic reexpression of both HBx-LINE1mutant and HBx-
LINE11–674 could readily restore the cell motile phenotype from
the inhibitory effect of si-HBx-LINE1 (Figure 6E), which further
enforced the oncogenicity of HBx-LINE1 as a hybrid RNA. The
expression of epithelial and mesenchymal markers in siHBx-
LINE1+HBx-LINE1mutant cells also confirms the lncRNA-like
function of HBx-LINE1. Western blot showed that siHBx-
LINE1-induced expression of E-cadherin and g-catenin was
downregulated in the presence of HBx-LINE1mutant. Inversely,
mesenchymal fibronectin regained upregulation in the rescue
of siHBx-LINE1+HBx-LINE1mutant (Figures 6F and 6G). Immuno-
fluorescence imaging showed that both full-length and stop
mutant HBx-LINE1 could revert nuclear localization of b-catenin
that corresponded to a rescue of active b-catenin levels (Figures
6H and 6I). In agreement with these findings, the TOP/FOPflash
assay also suggested an increase in b-catenin activity in siHBx-
LINE1+HBx-LINE1 and siHBx-LINE1+HBx-LINE1mutant com-
pared to siHBx-LINE1-treated cells (Figure 6J).
To rule out the possible involvement of microRNA in the func-
tional phenotypes observed, we conducted in vitro Drosha/Dicer
experiments for microRNA production from endogenous cleav-
age of HBx-LINE11–674. From northern blotting, we did not find
enzymatic cleavage of full-length HBx-LINE1 into small 18–
22 nt fragments, which suggested the lack of hairpin folding of
HBx-LINE11–674 for microRNA maturation (Figure S5). Our re-
sults would hence support a functional role for HBx-LINE1 as
an lncRNA-like transcript in modulating HCC cell motility and
growth.
To gain insight into the action of HBx-LINE1, we performed
expression profiling of siHBx-LINE1- and siMock-treated cells.
KEGG analysis (http://www.genome.jp/kegg) of differentially ex-
pressed genes indicated pathways under the modulation of
HBx-LINE1 (Figure 6K). RT-PCR verified an effect of siHBx-
LINE1 on the upregulation of Wnt inhibitors WIF1 and ATM and
downregulation of ZEB1, TAL2, and TCF3 (Figure 6L). To further
substantiate an effect onWnt signaling, we examined expression
of c-Myc and cyclin D1, two well-known direct targets of b-cat-
enin, and ZEB1, which is amaster regulator of EMT.Western blot
showed reduced levels of c-Myc, cyclin D1, and ZEB1 following
HBx-LINE1 knockdown in HKCI-4, whereas upregulation of
these proteins was readily detected when HBx-LINE1 was over-
expressed in L02 (Figure 6M).(D) Effect of HBx-LINE11–674 and HBx-LINE1mutant expression on the colony-form
(E) Rescue of the migratory phenotype from ectopic transfection of HBx-LINE11
(F and G) Western analysis for E-cadherin, g-catenin, and fibronectin, and densi
(H) Immunofluorescence staining for b-catenin localization. The scale bar repres
(I and J) Western blot and TOP/FOPflash assay for active b-catenin.
(K) Analysis of gene expression profiling for affected pathways by HBx-LINE1.
(L) Selected candidates were verified by qPCR.
(M) Western analysis of b-catenin targets c-Myc, cyclin D1, and ZEB1 in knockd
All data shown represent mean ± SEMvalues from three independent experiments
Table S4.HBx-LINE1 Increases Risk of HCC Development
Upon diethylnitrosamine (DEN)-induced HCC formation, gross
liver morphology of HBx-LINE1 and wild-type mice showed
tumor development at 8months. Figure 7A shows gross features
and histology of the murine HCC tumors formed. HBx-LINE1
transgenic mice from three strains were found to be consistently
more susceptible to DEN-induced tumor formation, where a
significantly higher number of HCC tumors was found in mice
with the transgene (mean 5.59, p = 0.0018) compared to wild-
type (mean 1.38) (Figure 7B). Immunohistochemical staining
further showed b-catenin nuclear localization in HCC tissue of
transgenic mice (Figure 7C). A significant difference in the nu-
clear positivity of b-catenin was further determined between
transgenic (n = 31/50 tumor nodules; 62%) and wild-type ani-
mals (n = 24/61 tumor nodules; 39%) (p = 0.018), which would
be suggestive of a more direct effect for HBx-LINE1 in modu-
lating Wnt/b-catenin signaling (Figure 7D). In situ hybridization
of tissues from HBx-LINE1 transgenic mice showed signals
mainly localized within the tumor cytoplasm (Figure 7E).
DISCUSSION
HBV is a hepadna virus that almost invariably integrates into the
HCC genome. Whereas integrations of HBV were once thought
to be random, recent genome resequencing of HCC has begun
to highlight recurrent integrated regions and greatly expanded
the list of targeted genes. In this study, using combined informa-
tion on read-pair mapping and breakpoint-spanning reads from
whole-transcriptome sequencing, we reconstructed viral and
human flanking sites and junctures, which could be indepen-
dently confirmed at both genomic DNA and transcribed RNA
levels (Figure S1A). In line with published results on whole-
genome sequencing of HBV-associated HCC, integration of
HBV upstream of TERT, within RALGPS1, and in the intergenic
region of chr.11q13 could also be found from our analysis (Jiang
et al., 2012; Sung et al., 2012; Toh et al., 2013). More interest-
ingly, we found active transcription of HBx-LINE1 from the viral
insertion into a normally silent intergenic region, chr.8p11.21.
In fact, the same integrated region chr.8p11.21 has also been re-
ported from a whole-genome sequencing study by Sung et al.
(2012) and a captured sequencing study of enriched HBV inte-
grants by Toh et al. (2013). In addition, previous PCR-based
cloning studies, despite their inherent low resolution, coincided
in suggesting regional chr.8p11 as a favorable viral integration
site (Murakami et al., 2005). Nevertheless, information on the
transcriptional effects resulting from viral insertion into this re-
gion remains minimally studied. Here we show de novo tran-
scription of LINE1 from chr.8p11.21. In addition to its mutagenic
role as mobile genetic elements (or retrotransposons), we reporting ability of L02 and HKCI-9 cells.
–674 and HBx-LINE1mutant in HKCI-4.
tometry measurements.
ents 10 mm.
own and overexpressed HBx-LINE1.
(***p < 0.001, **p < 0.01, *p < 0.05; n.s., no significance). See also Figure S5 and
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Figure 7. HBx-LINE1 Transgene Increases
Susceptibility to DEN-Induced HCC Develop-
ment
(A) Typical gross morphology of liver tumors from
DEN treatment at 8 months in HBx-LINE1 trans-
genic (upper right) or wild-type (upper left) male
mice. Arrowheads indicate macroscopic HCC
lesions. Lower: histology of a representative HCC
tumor nodule. Lower left: intermediate-power view
of HCC tumor (H&E stain). Lower right: high-power
view of HCC histology (H&E stain).
(B) The average number of HCC tumors per mouse
is shown with the mean value highlighted (unpaired
t test, **p = 0.0018).
(C) Immunohistochemical staining of transgenic and
wild-type liver sections using anti-b-catenin anti-
body. Clear nuclear staining of b-catenin in tumor
lesions was found in transgenic HCC tumors (de-
noted by arrowheads) but not in adjacent non-
tumoral liver (TN1 and TN2) and wild-type liver.
(D) Frequency of tumor nodules harboring positive
nuclear staining for b-catenin in transgenic mice
compared to wild-type mice (c2, *p = 0.018).
(E) In situ hybridization for HBx-LINE1 in T and
TN (top). Subcellular localization of HBx-LINE1
is mainly in the cytoplasm of T (middle) and TN
(bottom).
The scale bars represent 50 mm.
Cancer Cell
Chimeric Transcription at Viral Integration Sitehere on oncogenic effects of LINE1 in the chimera with HBx.
Based on our results, we believe that viral-induced transcription
of fusion hybrids may potentially unveil an additional layer of
transcript expression in HBV-associated pathogenesis.
The fact that HBV integrations have been mapped mostly to
noncoding repetitive regions has dampened research interest
in further investigation for many years. This was largely attributed
to postulations that suggested viral DNA insertions merely
allowed persistence of HBV in the host (Feitelson and Lee,
2007) or simply induced a more generalized phenomenon of
fragile chromosomes (Kremsdorf et al., 2006). The significance
of integrants in intronic or intergenic regions would seem to
have been underestimated. In this study, our analysis suggests
that HBx-LINE1 transcription can provide a selective advantage346 Cancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc.during tumorigenesis, rather than being a
byproduct event from random insertion.
HBx-LINE1 transcription occurred through
genomic insertion of truncated HBx in tan-
dem with the 50 end HBx promoter, which
might underscore the viral activated tran-
scription of an otherwise nontranscribing
human LINE1 repetitive sequence. The
full-length HBx-LINE1 transcript contained
a 30 end polyadenylation signal and poly(A)
tail, which would signify the process of
mature RNA production. Whereas previ-
ous studies of HBV integrants have re-
ported a low frequency of recurring cellular
integrations, we detected recurrent HBx-
LINE1 expression in 23.3%of HBV-associ-
ated HCC, suggesting a preferential site of
insertion. Cox regression analysis furthersuggested HBx-LINE1 as an independent prognostic factor for
predicting shorter survival of HCC patients. We also demon-
strated from extensive in vitro functional investigations that
HBx-LINE1 holds an important role in promoting tumor growth
and as a mediator of cell motility through the EMT process.
This behavioral change is likely through activation of Wnt/b-cat-
enin signaling, of which we showed expression of c-Myc, cyclin
D1, and ZEB1 can be spontaneously modulated by HBx-LINE1.
In inducing an EMT, ZEB1 is known not only to transcriptionally
repress epithelial markers such as E-cadherin but also to acti-
vatemesenchymal genes (Sa´nchez-Tillo´ et al., 2011). Of interest,
nuclear translocated b-catenin was reported to induce ZEB1
expression by direct binding to the ZEB1 promoter region
(Sa´nchez-Tillo´ et al., 2011). An effect of HBx-LINE1 on ZEB1
Cancer Cell
Chimeric Transcription at Viral Integration Sitethrough b-catenin activation is hence likely. In fact, aberrant acti-
vation of Wnt/b-catenin signaling is a major pathway in the onco-
genesis of HBV-associated HCC (Whittaker et al., 2010). Nuclear
and/or cellular b-catenin accumulation, a hallmark of activated
canonical Wnt signaling, has been observed in 65% of HCC
tumors (Devereux et al., 2001; Wong et al., 2001). However,
mutations of the b-catenin gene are found in only 13% of
HBV-associated HCCs (Huang et al., 2012; Wong et al., 2001),
suggesting that regulatory mechanisms other than b-catenin
mutations are likely involved in activating Wnt signaling. We hy-
pothesize here that HBx-LINE1, because of its frequent expres-
sion in HCC, may represent another upstream component in the
activation of the Wnt/b-catenin cascade. Studies have also re-
ported that HBV integration can be found during the course of
chronic infection and hence be considered an early carcinoge-
netic event (Bre´chot et al., 2000). In linewith this notion, transfec-
tion of HBx-LINE1 into the immortalized hepatocyte cell line L02
promoted colony growth. Moreover, functional involvement of
HBx-LINE1 in promoting cancer susceptibility was substantiated
in a transgenic model, where DEN-induced HCC tumor forma-
tions were significantly higher in mice with the HBx-LINE1 trans-
gene. Taken together, our data highlight the importance of the
HBx-LINE1 transcript in conferring oncogenic advantages that
may represent an elemental predisposing factor in the initiation
and progression of HCC.
In addition to the aforementioned findings, this study further
demonstrates that proteins translated from HBx-LINE1 cannot
account for the functional phenotypes observed. Nevertheless,
HBx-LINE1 translates an 11.4 kDa C-terminal truncated HBx.
Many studies have shown that C-terminal truncated HBx protein
holds oncogenic properties in HCC pathogenesis, although the
degree of truncation varies with function. Given that the major
functional breakpoints in primary HCCs are between 125 and
135 amino acids (Sze et al., 2013), the truncated HBx translated
from our current HBx-LINE1 chimera, at a breakpoint of 99
amino acids, may well haveminimized its tumor-promoting func-
tion with an overall smaller HBx protein translated. Interestingly,
results obtained with the HBx-LINE1 stopmutant showed similar
functional phenotypes as HBx-LINE11–674, which accentuate the
pathogenic role of HBx-LINE1 as an lncRNA-like transcript.
Recent transcriptome studies have begun to highlight abundant
expression of lncRNA in the mammalian genome. There is also
increasing evidence highlighting vital roles for lncRNA in regu-
lating cellular processes and their expression in contributing to
disease phenotypes such as cancer (Braconi et al., 2011;
Ørom et al., 2010). To date, only a few lncRNAs, namelyHOTAIR,
HULC, H19, and TUC338, have been studied in HCC (Braconi
et al., 2011; Matouk et al., 2007; Panzitt et al., 2007; Yang
et al., 2011). The regulatory roles of most lncRNAs in liver carci-
nogenesis are therefore still largely unexplored. Adding to this
repertoire, our present study isolated a chimeric transcript that
holds functional advantages. Because protein encoded by
HBx-LINE1 cannot account for the tumorigenic effects, the
oncogenicity instead is directly dependent on the hybrid RNA;
this underlines the activity of HBx-LINE1 as an lncRNA-like tran-
script. We hence report here that HBV insertion into a host
genome can incite chimeric transcription, and possibly high-
lights another level of intricacy in the production of functional
hybrid RNAs in cancer.It is known that human LINE-1 retrotransposons are a major
source of endogenous mutagens (Burns and Boeke, 2012; Levin
and Moran, 2011). In HCC, LINE1 has recently been shown to be
a crucial source ofmutations that can reduce the tumor-suppres-
sive capacity of somatic cells (Shukla et al., 2013). Here we show
oncogenic activity of LINE1 as a chimera with HBV, which poten-
tially may signify a functionally distinct class of lncRNA-like
transcripts. Our current study also provides evidence of the
molecular complexity of HBV integrations, where virus inserted
into the genome could create a cryptic splice site or be tran-
scribed as a complex fusion when genomic rearrangements
are involved. Many viral-human chimeras identified also showed
a microhomology sequence at both breakpoint junctions. It is
plausible that the mechanism of HBV insertion into the host
genome was likely generated via the mediation of a microhomol-
ogy during break-induced replication repair (Hastings et al.,
2009). Moreover, the chimeric transcripts determined showed
an identical sequence to the flanking viral-human DNA fragment,
which suggests a direct readthrough transcription from the site of
genomic integration. In summary, our results show a common
transcription of a viral-human chimera in response to HBV
genome integration. Our study, together with recent results
from genome sequencing, provides a basis for investigative ana-
lyses that may lead to further understanding of the effect by
which HBV insertion supports cancer development.
EXPERIMENTAL PROCEDURES
Transcriptome Sequencing
Six HCC cell lines, namely HKCI-1, HKCI-4, HKCI-5B, HKCI-7, HKCI-9, and
HKCI-11, were subjected to whole-transcriptome sequencing. These cell lines
were developed from HBV-infected HCC patients who underwent curative
surgery at Prince of Wales Hospital, Hong Kong. Because these cell lines
were established within our institute (Chan et al., 2006; Pang et al., 2002),
the early culture passages were accessible and had been used for the
sequencing described here. Briefly, TRIzol-extracted RNA was subjected to
sequencing library preparation using an Illumina TruSeq RNA Sample Prepa-
ration Kit according to the manufacturer’s instructions. RNA-seq was per-
formed on an Illumina HiSeq 2000 platform, generating paired-end sequence
reads of read length 101 bp with an average insertion size of 300 bp. On
average, 127 M reads were obtained per sample with mappable reads at an
average of 92.87%. Detailed sequencing statistics are shown in Table S2.
Detection of Viral-Human Fusion Transcripts by ViralFusionSeq
The analysis tool for discovery of viral-human fusion transcript in this study,
ViralFusionSeq, was recently published by our group (Li et al., 2013). VFS
pinpoints the locations of viral-human fusion events by integrating two comple-
mentary approaches into the analysis: breakpoint-spanning reads and discor-
dant read pairs. For paired-end sequencing, a majority of reads in a pair would
be mapped, within the expected insertion size, together onto either the human
or viral genome. A possible viral-human fusion is implied by (1) mapping of two
reads in a pair separately onto the viral and human genomes; and/or (2) partial
mapping of a sequence read within a given pair onto both the viral and human
genomes. VFS exploits these two events: the read-pair (RP) analysis module to
tackle the former, and utilizes the postalignment sequences in the clipped-seq
(CS) analysis module to interrogate the latter case. Finally, a targeted de novo
assemblyusingboth theRPandCS readswasperformed for each fusioncandi-
date to reconstruct the fusion transcript. Details of the VFS algorithm and
analytical methods are described in Supplemental Experimental Procedures.
Detection of the HBx-LINE1 Transcript in HCC Tumors
Tumorous liver tissues were collected from 90 patients who underwent cura-
tive surgery for HCC at Prince of Wales Hospital, Hong Kong. Informed con-
sent was obtained from each recruited patient and the study protocol wasCancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc. 347
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of Hong Kong. Demographics of the patient cohort are shown in Table S3. The
diagnosis of HCC was confirmed by histology examination. The patients re-
cruited were all chronic carriers of HBV. The HBx-LINE1 transcript in HCC
tumors was analyzed by RT-PCR. Reverse-transcribed cDNA was amplified
by a hemi-nested PCR using specific primers designed for the juxtaposed
positions of the viral-human flanking junction. Details are described in Supple-
mental Experimental Procedures.
RNAi Knockdown of HBx-LINE1
Two oligonucleotides targeting the HBx-LINE1 transcript were designed:
siHBx-LINE1a (289–313 bp, 50-ACCACCGUGUUGUUGAGGAUGUGAA-30 )
and siHBx-LINE1b (622–646 bp, 50-UCGUGGAUGGAAUCGAAGAACA
UUA-30). HKCI-4 cultured in complete AIM-V medium (Life Technologies)
was transfected with siHBx-LINE1a or siHBx-LINE1b using Lipofectamine
2000 (Invitrogen). Stealth RNAi siRNA negative control was used as siMock.
The efficacy of transcript knockdown was confirmed and monitored by RT-
PCR. Effects of HBx-LINE1 knockdown on function, including cell viability
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Matri-
gel cell invasion, and Transwell cell migration, were examined. Details are
described in Supplemental Experimental Procedures.
Expression Vector Constructions and Ectopic Transfection
A number of plasmids were constructed based on the complete sequence ob-
tained of HBx-LINE1 (674 bp). These included a full-length HBx-LINE11–674
and variants HBx1–297 and LINE1295–674, each of which constituted the viral
and human component along with the GTG microhomology, and HBx-
LINE11–312*, which contained the HBx fragment and a partial sequence of
LINE1 prior to a stop codon on the human portion. Details of the cloning
maps are shown in Figure 5A, and primers are listed in Supplemental Experi-
mental Procedures. Each plasmid was cloned into a pEGFP-C2 expression
vector (Clontech) with an EGFP sequence to examine tag-fused protein trans-
lation. The series of plasmids was also cloned into another derivative, pEGFP-
C2R(-), with a deleted EGFP-coding sequence for use in transfection assays.
A mutant HBx-LINE1 with a stop codon introduced into the HBx region was
also constructed and is shown in Figure 6A. This aimed at producing a full-
length RNA transcript in the absence of encoded protein. The HBx-LINE1
mutant was cloned by site-directed mutagenesis using the Transformer Site-
Directed Mutagenesis Kit (Clontech) according to the manufacturer’s instruc-
tions. The HBx-LINE1 construct was used as a template for annealing of
the mutagenic primer (50-GGCTGCTAGGGTGTGATGCCAACTGGATCCT-30;
the stop codon is underlined). One base substitution was introduced into the
HBx region, resulting in only a small peptide of 5 amino acids being expressed
from the HBx-LINE1 construct. This construct is referred to as the HBx-LINE1
stop mutant or HBx-LINE1mutant. All cloned plasmids in pEGFP-C2 and
pEGFP-C2R(-) were sequence verified and their expression was confirmed
by RT-PCR in transfected cells. Expression vectors were transfected into
L02, HKCI-9, and HKCI-1 using Lipofectamine 2000 (Invitrogen).
Liver-Specific Transgenic HBx-LINE1 Mice
Full-length HBx-LINE1was cloned into an expression vector containing a liver-
specific transthyretin promoter to generate an HBx-LINE1 transgene. Full-
length HBx-LINE1 was amplified using forward and reverse primers containing
the NruI restriction site. Transgenic mice were made following the standard
protocol outlined (Hogan et al., 1986), and three strains were developed for
the purpose of hybrid HBx-LINE1 investigations. PCR of tail DNA was em-
ployed to screen for positive transgenic mice. Mice of age 15 days received
a single intraperitoneal injection of DEN (5 mg/kg body weight; Sigma). After
8 months, mice were sacrificed and liver RNA was extracted to confirm
HBx-LINE1 expression. The presence of surface nodules in HBx-LINE1 and
wild-type transgenic mice was evaluated and compared. Development of
HCC was confirmed histologically. All experimentation was conducted in
accordance with guidelines of the Animal Experimentation Ethics Committee
of the Chinese University of Hong Kong.
Statistics
Data are presented as mean ± SEM from at least three independent experi-
ments. Kaplan-Meier survival plot and log-rank test were performed, together348 Cancer Cell 25, 335–349, March 17, 2014 ª2014 Elsevier Inc.with univariate and multivariate Cox regression analysis, to establish prog-
nostic significance of HBx-LINE1 in patients. Student’s t test compared
experimental data obtained between groups. A p value less than 0.05 was
considered statistically significant.
Other Experimental Assays
Other supporting verifications and functional assays are described in Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
Sequencing data on six HBV-positive HCC cell lines have been deposited in
the Sequence Read Archive under accession number SRP023539.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.01.030.
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